Xu MengFei, van de Wiel Mark A, Martinovičová Dominika, Huseinovic Angelina, van Beusechem Victor W, Stalpers Lukas J A, Oei Arlene L, Steenbergen Renske D M, Snoek Barbara C
Amsterdam UMC, Vrije Universiteit Amsterdam, Pathology, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
Cancer Center Amsterdam, Imaging and Biomarkers, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
Mol Ther Nucleic Acids. 2025 Mar 5;36(2):102500. doi: 10.1016/j.omtn.2025.102500. eCollection 2025 Jun 10.
Chemoradiotherapy is the standard of care for many locally advanced cancers, including cervical and head and neck cancers, but many patients cannot tolerate chemotherapy. Clinical trials have shown that radiotherapy combined with hyperthermia (thermoradiotherapy) may be equally effective, yet it yields a suboptimal overall survival of patients, emphasizing the need for improvement. MicroRNAs (miRNAs), short non-coding RNA sequences, are often dysregulated in cancer and exhibit significant potential as radiosensitizers by targeting genes associated with the DNA damage response. In this study, high-throughput miRNA screening of four cervical cancer cell lines identified 55 miRNAs with significant sensitizing potential, with 18 validated across 10 additional cancer cell lines (6 cervical and 4 head and neck). Functional studies of 6 miRNAs, including miR-16, miR-27a, miR-181c, miR-221, miR-224, and miR-1293, showed that they reduced DNA damage repair by downregulating ATM, DNA-PKcs, Ku70/80, and RAD51. Additionally, differential expression of miR-27a, miR-221, and miR-224 in treatment-sensitive versus treatment-resistant patients indicated their predictive biomarker potential for treatment response of cervical cancer patients. Conclusively, this study has identified 18 promising miRNAs for the development of sensitizers for thermoradiotherapy and may provide potential biomarkers for predicting treatment response in locally advanced cancers.
化疗放疗是包括宫颈癌和头颈癌在内的许多局部晚期癌症的标准治疗方法,但许多患者无法耐受化疗。临床试验表明,放疗联合热疗(热放疗)可能同样有效,但患者的总生存率仍不理想,这凸显了改进的必要性。微小RNA(miRNA)是短的非编码RNA序列,在癌症中常常失调,并通过靶向与DNA损伤反应相关的基因,展现出作为放射增敏剂的巨大潜力。在本研究中,对四种宫颈癌细胞系进行高通量miRNA筛选,鉴定出55种具有显著增敏潜力的miRNA,其中18种在另外10种癌细胞系(6种宫颈癌和4种头颈癌)中得到验证。对包括miR-16、miR-27a、miR-181c、miR-221、miR-224和miR-1293在内的6种miRNA的功能研究表明,它们通过下调ATM、DNA-PKcs、Ku70/80和RAD51来减少DNA损伤修复。此外,miR-27a、miR-221和miR-224在治疗敏感与治疗耐药患者中的差异表达表明,它们对宫颈癌患者的治疗反应具有预测生物标志物潜力。总之,本研究已鉴定出18种有前景的miRNA,可用于开发热放疗增敏剂,并可能为预测局部晚期癌症的治疗反应提供潜在生物标志物。